Commentary: Alternative safe, effective and cost-efficient dosing for eptifibatide in low-risk patients

J Invasive Cardiol. 2006 Oct;18(10):492-3.
No abstract available

Publication types

  • Comment

MeSH terms

  • Coronary Artery Disease / therapy*
  • Cost-Benefit Analysis
  • Drug Costs*
  • Eptifibatide
  • Humans
  • Peptides / economics
  • Peptides / therapeutic use*
  • Platelet Aggregation Inhibitors / economics
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Stents*
  • Treatment Outcome

Substances

  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Eptifibatide